Chad J. Kolean - 07 Jul 2026 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)

Reporting relationship: CFO
Issuer ticker: CLRB
Reported as of: 07 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jul 2026, 21:13:50 UTC
Prior SEC filing: 03 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Chad Kolean

Key filing fact

Chad J. Kolean filed Form 4 for Cellectar Biosciences, Inc. (CLRB) on 08 Jul 2026.

Key facts

This page summarizes Chad J. Kolean's Form 4 filing for Cellectar Biosciences, Inc. (CLRB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jul 2026, 21:13.

Change

Previous filing in this sequence was filed on 03 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001616753 Primary reporting owner

Kolean Chad J

Relationship: CFO
Address: C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK
Signature: /s/ Chad Kolean
Signature date: 08 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLRB transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +92,000
Change %
Price: $0.000000^*
Shares after: 92,000
Date: 07 Jul 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 92,000
Exercise price: $3.14
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.

Footnote F2

This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026.